Pharmaceutical Technologies
- Funder
- National Science Foundation (SBIR/STTR)
- Award amount
- Not specified
- Deadline
- July 7, 2027
- Eligible countries
- United States
Summary
SBIR/STTR topic (National Science Foundation), Phase I and II. Open to U.S. small businesses; STTR projects partner with a U.S. research institution. Opens: May 22, 2026. Closes: July 7, 2027. The Pharmaceutical Technologies topic covers a wide range of technology areas that advance the discovery, formulation, and manufacture of novel drugs, moieties, compounds, products, processes, platforms or services that will improve the selection, quality or price of pharmaceutical and biologic therapies. The Pharmaceutical Technologies topic is not aimed at supporting or conducting clinical trials, clinical efficacy and safety studies, the development of pre-clinical or clinical-stage drug candidates, work on medical devices or schedule I substances, or work performed primarily for regulatory purposes. The NSF SBIR/STTR program no longer supports the development of specific therapeutic molecules. Drug Discovery and Manufacturing are still supported by the program. Official solicitation: https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology/nsf26-510/solicitation
Summary as listed by the funder. Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement →What U.S. National Science Foundation reviewers look for
- Intellectual Merit: the potential to advance knowledge.
- Broader Impacts: the potential to benefit society, with named partners, numbers and a way to assess them.
- For both, reviewers weigh the quality of the plan, the team's qualifications and resources, and how success will be measured.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and Lantern Grants scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free